National Comprehensive Cancer Network



NCCN Oncology Research Program (ORP)
NCCN ORP Recent News
NCCN ORP Affiliate Research Consortium
NCCN ORP Scientific Publications
NCCN ORP for Industry
NCCN ORP Investigator Steering Committee
NCCN ORP Testimonials
NCCN Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
NCCN Informed Consent Language Database
NCCN Specialized Imaging Research Consortium™ (SIRC)
NCCN ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Updates to NCCN Guidelines for Cancer- and Chemotherapy- Induced Anemia and NCCN Guidelines for Occult Primary (Cancer of Unknown Primary)

The NCCN Clinical Practice Guidelines in Oncology™ for Cancer- and Chemotherapy- Induced Anemia and the NCCN Clinical Practice Guidelines in Oncology™ for Occult Primary (Cancer of Unknown Primary) have been updated and published by the National Comprehensive Cancer Network.

The current version of the NCCN Guidelines for Cancer- and Chemotherapy- Induced Anemia is now v.1.2010. Updates included reference to new meta-analyses that further confirmed increased mortality risks associated with ESAs and treatment recommendations for no iron deficiency in asymptomatic patients with risk factors for developing anemia.

The current version of the NCCN Guidelines for Occult Primary is now v.1.2010. Updates include recommendations that neuroendocrine tumors of unknown specific cell type that are poorly differentiated (high grade or anaplastic) or small cell subtype should be managed according to the NCCN Guidelines for Small Cell Lung Cancer and moderate or well differentiated neuroendocrine tumors of unknown specific cell type should be managed according to Carcinoid Tumors as described in the NCCN Guidelines for Neuroendocrine Tumors.